The child was suffering from a complex congenital heart disease.
Lucknow, 16th September, 2022: Medanta Hospital, Lucknow has recently treated a 9-day-oldbaby girl who was suffering from complex cyanotic congenital heart disease with duct dependent pulmonary circulation. The team of experts includingDr. Gauranga Majumdar, Director – Cardiothoracic and Vascular Surgery, Dr. Aakash Pandita,Senior Consultant and Head – Neonatology and Dr. Roli Srivastava, Consultant -Pediatric Cardiology, were part of this complex surgery.
Dr. Gauranga Majumdar said “The child came to us on day 5 of life with complaints of bluish discoloration of the body. On after further investigation, it was found the baby was suffering from complex cyanotic congenital heart disease namely double outlet right ventricle (DORV), ventricular septal defect (VSD), and pulmonary atresia (PA). Immediate surgery was planned as patent ductus arteriosus (PDA) – a small artery which provides blood flow to the lungs was closing and baby’s oxygen saturation was falling below 50%. The new-born whowas around 2kg when admitted,underwent shunt surgery- a lifesaving procedure, and was discharged within 10 days of admission.”
Dr. Aakash Pandita said “Post-procedure the baby was shifted to Neonatal intensive care unit (NICU) on a mechanical ventilator and was discharged in stable condition. On follow up, the baby is gaining weight and is doing well. Neonatal cardiac surgeries are complex and require a level 3B NICU care, in addition to coordinated effort of cardiothoracic and vascular surgery and paediatric cardiology teams. We could successfully treat this case as Medanta-Lucknow is equipped with all these facilities.
Dr Roli Srivastava said, “There are some heart problems in new-borns in which the arteries supplying oxygen to the lungs are not formed so the baby becomes oxygen deficient soon after birth. There is a small artery which is called PDA. It supplies blood flow to lungs for the first few days of life. But this PDA closes soon after birth in babies with complex heart diseases. We have to thus create a shunt between the system and pulmonary circulation to keep the lung flow going on. ”
Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third and fourth-highest civilian awards in India and B C Roy award in recognition
of his distinguished contribution to medicine, Global Health Limited (the “Company”) is one of the largest private multi-speciality tertiary care providers operating in the North and East regions of India, with key specialties of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urology, according to the report titled “An assessment of the healthcare delivery market in India, September 2021” by CRISIL Limited.
Under the “Medanta” brand, the Company has a network of five hospitals currently in operation (Gurugram, Indore, Ranchi, Lucknow, and Patna). Spanning an area of 3.7 million sq. ft., its operational hospitals have 2,176 installed beds as on March 31, 2021. It also has one hospital planned for development in Noida. As of March 31, 2021, the Company provides healthcare services in over 30 medical specialties and engages over 1,100 doctors led by highly experienced department heads.
The Company’s facilities have received national and international accreditations, including the NABH accreditation for the hospital and blood bank at Gurugram. The Gurugram hospital was ranked as the best private hospital in India for three consecutive years in 2020, 2021 and 2022, and was the only Indian private hospital to be featured in the list of top 150 global hospitals in 2022 by Newsweek. The Gurugram hospital was also featured in the list of world’s best specialized hospitals for cardiology in 2021, and cardiology and neurology in 2022 rankings released by Newsweek.
Certain Information in this press release is from the report titled “An assessment of the healthcare delivery market in India, September 2021” by CRISIL Limited, which is subject to the following disclaimer:
CRISIL Research, a division of CRISIL Limited (CRISIL) has taken due care and caution in preparing this report (Report) based on the Information obtained by CRISIL from sources which it considers reliable (Data). CRISIL does not guarantee the accuracy, adequacy or completeness of any material contained in or referred to in Report. This Report is not a recommendation to invest / disinvest in any entity covered in the Report and no part of this Report should be construed as an expert advice or investment advice or any form of investment banking within the meaning of any law or regulation. CRISIL especially states that it has no liability whatsoever to the subscribers / users / transmitters/ distributors of this Report. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary permission and/or registration to carry out its business activities in this regard. Global Health Limited will be responsible for ensuring compliances and consequences of non-compliances for use of the Report or part thereof outside India. CRISIL Research operates independently of, and does not have access to information obtained by CRISIL Ratings Limited / CRISIL Risk and Infrastructure Solutions Ltd (CRIS), which may, in their regular operations, obtain information of a confidential nature.